{"protocolSection": {"identificationModule": {"nctId": "NCT01328964", "orgStudyIdInfo": {"id": "112608"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population", "officialTitle": "Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-03-04", "studyFirstSubmitQcDate": "2011-04-01", "studyFirstPostDateStruct": {"date": "2011-04-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-04-08", "resultsFirstSubmitQcDate": "2011-04-08", "resultsFirstPostDateStruct": {"date": "2011-05-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-06-06", "lastUpdatePostDateStruct": {"date": "2017-07-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The objective of this study is to compare asthma-related exacerbations (emergency department (ED) or inpatient (IP) visit) and related cost in pediatric patients aged 4-11 years that received either fluticasone propionate 44 mcg (FP44) or budesonide (BUD) or montelukast (MON). This retrospective observational cohort analysis utilizes a large managed care database with linked pharmacy and medical claims. Patients with \u2265 1 pharmacy claim FP44 or BUD or MON between January 1, 2000 through June 30, 2008 (4-11 years old at time of index) with \u2265 1 diagnosis for asthma (ICD-9 493.xx) in the pre-index period and continuously eligible to receive healthcare services for 1-year pre-index and at least 30 days post-index. Dose of each inhaled corticosteroid was not known in the database. Follow-up was defined for each patient as the period beginning with the index date and ending with the last date of continuous claims history, switch to another asthma controller medication, or claim for an asthma related event (ED/IP visit or OCS use) post-index, whichever occurred first."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["pediatric", "asthma", "outcomes", "inhaled cortcosteroids"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 9906, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Children Ages 4-11 with asthma", "description": "Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy", "interventionNames": ["Drug: Fluticasone propionate", "Drug: Budesonide", "Drug: Montelukast"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone propionate", "description": "fluticasone propionate 44 mcg", "armGroupLabels": ["Children Ages 4-11 with asthma"], "otherNames": ["Flovent\u00ae is a registered trademark of GlaxoSmithKline"]}, {"type": "DRUG", "name": "Budesonide", "description": "budesonide", "armGroupLabels": ["Children Ages 4-11 with asthma"], "otherNames": ["Singulair\u00aeis a registered trademark of Merck and Company"]}, {"type": "DRUG", "name": "Montelukast", "description": "montelukast", "armGroupLabels": ["Children Ages 4-11 with asthma"], "otherNames": ["Rhinocort\u00ae is a registered trademark of AstraZeneca"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Asthma-related Hospitalizations, Asthma-related Emergency Department (ED) Visits, and Combined Hospitalizations/ED Visits Represented Per 100 Person Years", "description": "The number of participants with an asthma-related event was computed during the follow-up period and was standardized by dividing by the total days of follow-up in each cohort since participants had different lengths of follow-up. Per 100 person years is equal to the percent of events that occurred during the observed time period of the study.", "timeFrame": "January 1, 2000 to June 30, 2008"}], "secondaryOutcomes": [{"measure": "Mean Monthly Asthma-related Costs (Pharmacy and Medical) During the Post-index Period", "description": "The mean total asthma costs are a sum of pharmacy and medical costs. Costs were determined monthly from the pharmacy and medical encounters recorded in the managed care insurance database. All costs were summed for each participant over the 3-12 month follow-up period (post-index period), and a mean monthly cost was calculated by dividing by the follow-up for each participant.", "timeFrame": "12 months prior to January 1, 2000 to June 30, 2008"}, {"measure": "Number of Asthma-related Hospitalizations, Asthma-related Emergency Department (ED) Visits, and Combined Hospitalizations/ED Visits Represented Per 100 Person Years", "description": "The number of participants with an asthma-related event was computed during the follow-up period and was standardized by dividing by the total days of follow-up in each cohort since participants had different lengths of follow-up. Per 100 person years is equal to the percent of events that occurred during the observed time period of the study.", "timeFrame": "12 months prior to January 1, 2000 to June 30, 2008"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* ICD-9 code for asthma\n* one or more outpatient pharmacy claims for fluticasone propionate 44mg or budesonide between January 1, 2000 and June 30, 2008\n* ages 4 to 11 years\n\nExclusion Criteria:\n\n* diagnosis of Cystic Fibrosis\n* \u2265 1 Rx claim for any asthma controller in the pre-index period", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"], "studyPopulation": "Claims related to pediatric patients age 4-12 in the database with one or more outpatient pharmacy claims for fluticasone propionate 44 micrograms (FP44) or budesonide (BUD) or montelukast (MON) between January 1, 2000 and June 30, 2008.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "This was a retrospective observational study utilizing a large managed care database with linked pharmacy and medical claims. The dose of each inhaled corticosteroid was not known in the database.", "groups": [{"id": "FG000", "title": "Fluticasone Propionate", "description": "Pediatric participants aged 4-11 years that received fluticasone propionate 44 micrograms (FP44) for the treatment of asthma"}, {"id": "FG001", "title": "Budesonide", "description": "Pediatric participants aged 4-11 years that received budesonide for the treatment of asthma"}, {"id": "FG002", "title": "Montelukast", "description": "Pediatric participants aged 4-11 years that received montelukast for the treatment of asthma"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2212"}, {"groupId": "FG001", "numSubjects": "3270"}, {"groupId": "FG002", "numSubjects": "4424"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2212"}, {"groupId": "FG001", "numSubjects": "3270"}, {"groupId": "FG002", "numSubjects": "4424"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Fluticasone Propionate", "description": "Pediatric participants aged 4-11 years that received fluticasone propionate 44 micrograms (FP44) for the treatment of asthma"}, {"id": "BG001", "title": "Budesonide", "description": "Pediatric participants aged 4-11 years that received budesonide for the treatment of asthma"}, {"id": "BG002", "title": "Montelukast", "description": "Pediatric participants aged 4-11 years that received montelukast for the treatment of asthma"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2212"}, {"groupId": "BG001", "value": "3270"}, {"groupId": "BG002", "value": "4424"}, {"groupId": "BG003", "value": "9906"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.18", "spread": "2.20"}, {"groupId": "BG001", "value": "7.30", "spread": "2.27"}, {"groupId": "BG002", "value": "7.21", "spread": "2.23"}, {"groupId": "BG003", "value": "7.23", "spread": "2.23"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "897"}, {"groupId": "BG001", "value": "1267"}, {"groupId": "BG002", "value": "1797"}, {"groupId": "BG003", "value": "3961"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1315"}, {"groupId": "BG001", "value": "2003"}, {"groupId": "BG002", "value": "2627"}, {"groupId": "BG003", "value": "5945"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Asthma-related Hospitalizations, Asthma-related Emergency Department (ED) Visits, and Combined Hospitalizations/ED Visits Represented Per 100 Person Years", "description": "The number of participants with an asthma-related event was computed during the follow-up period and was standardized by dividing by the total days of follow-up in each cohort since participants had different lengths of follow-up. Per 100 person years is equal to the percent of events that occurred during the observed time period of the study.", "populationDescription": "Members of the IMS Life Link Health Plans Claims Database (containing data from \\>=90 managed healthcare plans, encompassing \\>=60 million lives) who had \\>=1 pharmacy claim during the study period. FSC participants were matched 1:2 to budesonide and montelukast separately, leading to different numbers analyzed for FSC dependent on cohort of interest.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "asthma events per 100 person years", "timeFrame": "January 1, 2000 to June 30, 2008", "groups": [{"id": "OG000", "title": "Fluticasone Propionate", "description": "Pediatric participants aged 4-11 years that received fluticasone propionate 44 micrograms (FP44) for the treatment of asthma"}, {"id": "OG001", "title": "Budesonide", "description": "Pediatric participants aged 4-11 years that received budesonide for the treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1635"}, {"groupId": "OG001", "value": "3270"}]}], "classes": [{"title": "Hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89"}, {"groupId": "OG001", "value": "0.61"}]}]}, {"title": "Emergency Department Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.35"}, {"groupId": "OG001", "value": "5.30"}]}]}, {"title": "Hospitalizations or Emergency Department Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.17"}, {"groupId": "OG001", "value": "5.85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The p-value is a comparison of the combined hospitalization/emergency department visit endpoint", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.51", "ciUpperLimit": "0.974"}]}, {"type": "SECONDARY", "title": "Mean Monthly Asthma-related Costs (Pharmacy and Medical) During the Post-index Period", "description": "The mean total asthma costs are a sum of pharmacy and medical costs. Costs were determined monthly from the pharmacy and medical encounters recorded in the managed care insurance database. All costs were summed for each participant over the 3-12 month follow-up period (post-index period), and a mean monthly cost was calculated by dividing by the follow-up for each participant.", "populationDescription": "Members of the IMS Life Link Health Plans Claims Database (containing data from \\>=90 managed healthcare plans, encompassing \\>=60 million lives) who had \\>=1 pharmacy claim during the study period. FSC participants were matched 1:2 to budesonide and montelukast separately, leading to different numbers analyzed for FSC dependent on cohort of interest.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "United States dollars", "timeFrame": "12 months prior to January 1, 2000 to June 30, 2008", "groups": [{"id": "OG000", "title": "Fluticasone Propionate", "description": "Pediatric participants aged 4-11 years that received fluticasone propionate 44 micrograms (FP44) for the treatment of asthma"}, {"id": "OG001", "title": "Budesonide", "description": "Pediatric participants aged 4-11 years that received budesonide for the treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1635"}, {"groupId": "OG001", "value": "3270"}]}], "classes": [{"title": "Monthly Medical Costs", "categories": [{"measurements": [{"groupId": "OG000", "value": "25", "spread": "126"}, {"groupId": "OG001", "value": "27", "spread": "166"}]}]}, {"title": "Monthly Pharmacy Costs", "categories": [{"measurements": [{"groupId": "OG000", "value": "20", "spread": "40"}, {"groupId": "OG001", "value": "32", "spread": "71"}]}]}, {"title": "Monthly Total Costs", "categories": [{"measurements": [{"groupId": "OG000", "value": "45", "spread": "136"}, {"groupId": "OG001", "value": "59", "spread": "186"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value is based on the differences in the total monthly asthma costs", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "-14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19", "ciUpperLimit": "-9"}]}, {"type": "SECONDARY", "title": "Number of Asthma-related Hospitalizations, Asthma-related Emergency Department (ED) Visits, and Combined Hospitalizations/ED Visits Represented Per 100 Person Years", "description": "The number of participants with an asthma-related event was computed during the follow-up period and was standardized by dividing by the total days of follow-up in each cohort since participants had different lengths of follow-up. Per 100 person years is equal to the percent of events that occurred during the observed time period of the study.", "populationDescription": "Members of the IMS Life Link Health Plans Claims Database (containing data from \\>=90 managed healthcare plans, encompassing \\>=60 million lives) who had \\>=1 pharmacy claim during the study period. FSC participants were matched 1:2 to budesonide and montelukast separately, leading to different numbers analyzed for FSC dependent on cohort of interest.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Asthma related events per100 person year", "timeFrame": "12 months prior to January 1, 2000 to June 30, 2008", "groups": [{"id": "OG000", "title": "Fluticasone Propionate", "description": "Pediatric participants aged 4-11 years that received fluticasone propionate 44 micrograms (FP44) for the treatment of asthma"}, {"id": "OG001", "title": "Montelukast", "description": "Pediatric participants aged 4-11 years that received montelukast for the treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2212"}, {"groupId": "OG001", "value": "4424"}]}], "classes": [{"title": "Hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.71"}, {"groupId": "OG001", "value": "0.62"}]}]}, {"title": "Emergency Department Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.40"}, {"groupId": "OG001", "value": "4.76"}]}]}, {"title": "Hospitalizations or Emergency Department Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.07"}, {"groupId": "OG001", "value": "5.29"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0495", "pValueComment": "P-value is based on the comparison of combined endpoint of hospitalization/emergency department visits", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.751", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.565", "ciUpperLimit": "0.999"}]}, {"type": "SECONDARY", "title": "Mean Monthly Asthma-related Costs (Pharmacy and Medical) During the Post-index Period", "description": "The mean total asthma costs are a sum of pharmacy and medical costs. Costs were determined monthly from the pharmacy and medical encounters recorded in the managed care insurance database. All costs were summed for each participant over the 3-12 month follow-up period (post-index period), and a mean monthly cost was calculated by dividing by the follow-up for each participant.", "populationDescription": "Members of the IMS Life Link Health Plans Claims Database (containing data from \\>=90 managed healthcare plans, encompassing \\>=60 million lives) who had \\>=1 pharmacy claim during the study period. FSC participants were matched 1:2 to budesonide and montelukast separately, leading to different numbers analyzed for FSC dependent on cohort of interest.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "United States dollars", "timeFrame": "12 months prior to January 1, 2000 to June 30, 2008", "groups": [{"id": "OG000", "title": "Fluticasone Propionate", "description": "Pediatric participants aged 4-11 years that received fluticasone propionate 44 micrograms (FP44) for the treatment of asthma"}, {"id": "OG001", "title": "Montelukast", "description": "Pediatric participants aged 4-11 years that received montelukast for the treatment of asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2212"}, {"groupId": "OG001", "value": "4424"}]}], "classes": [{"title": "Monthly Medical Costs", "categories": [{"measurements": [{"groupId": "OG000", "value": "26", "spread": "165"}, {"groupId": "OG001", "value": "27", "spread": "176"}]}]}, {"title": "Monthly Pharmacy Costs", "categories": [{"measurements": [{"groupId": "OG000", "value": "21", "spread": "87"}, {"groupId": "OG001", "value": "48", "spread": "75"}]}]}, {"title": "Monthly Total Costs", "categories": [{"measurements": [{"groupId": "OG000", "value": "48", "spread": "190"}, {"groupId": "OG001", "value": "75", "spread": "197"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-value is based on difference in total monthly asthma costs", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "-28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28", "ciUpperLimit": "-27"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "This was a retrospective observational study utilizing a large managed care database with linked pharmacy and medical claims. Serious adverse events and non-serious adverse events were not collected.", "eventGroups": [{"id": "EG000", "title": "Fluticasone Propionate", "description": "Pediatric participants aged 4-11 years that received fluticasone propionate 44 micrograms (FP44) for the treatment of asthma", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Budesonide", "description": "Pediatric participants aged 4-11 years that received budesonide for the treatment of asthma", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG002", "title": "Montelukast", "description": "Pediatric participants aged 4-11 years that received montelukast for the treatment of asthma", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000019819", "term": "Budesonide"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M250", "name": "Fluticasone", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}]}}, "hasResults": true}